A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
NCT06055374 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2024-08-09
Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of a multiple SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)
Conditions
Interventions
- DRUG
-
BxC-I17e
Pharmaceutical form : solution for injection
- DRUG
-
Pharmaceutical form : solution for injection
Sponsors & Collaborators
-
Brexogen Inc.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-05-01
- Primary Completion
- 2025-04-30
- Completion
- 2025-08-30
- FDA Drug
- Yes
More Related Trials
-
Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis
NCT06487000 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT06397911 ·Status: RECRUITING ·Phase: PHASE2
-
Study in Subjects With Moderate Atopic Dermatitis
NCT03859986 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
NCT07217015 ·Status: RECRUITING ·Phase: PHASE2
-
Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis
NCT03824405 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis
NCT06468956 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis
NCT04313400 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT04875169 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis
NCT05240300 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
NCT03011892 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis
NCT02087943 ·Status: COMPLETED ·Phase: PHASE2
-
The Study of CM326 in Moderate-to-severe Atopic Dermatitis
NCT05671432 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis
NCT06248814 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118 ·Status: RECRUITING ·Phase: PHASE3
-
Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07054736 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06832618 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
NCT06224348 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
NCT07309055 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis
NCT06012812 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03864627 ·Status: TERMINATED ·Phase: PHASE2
-
Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis
NCT03703102 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis
NCT07211542 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT03738423 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
NCT03054428 ·Status: COMPLETED ·Phase: PHASE3